Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Bipolar Depression (CannaBiD Study)
2015-000465-31Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Cannabidiol add-on with Placebo add-on (2 arms). Primary endpoint: change in HDRS-17 score. Started Mar 2016; status: terminated.
02
Drugs
cannabidiol
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2015-000465-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000465-31.